A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids
Study of Experimental Gel Drug in Subjects with Persistently Active Systemic Lupus Erythematosus (SLE)
Sponsor: Mallinckrodt
Enrolling: Male and Female Patients
Study Length: 3 Years
IRB Number: AAAR2853
U.S. Govt. ID: NCT02953821
Contact: Anca Askanase, MD: 212-342-6815 / ada20@cumc.columbia.edu
Additional Study Information: We are studying a medication to see if it is effective in reducing the disease activity of systemic lupus erythematosus (SLE), which is the most common form of lupus. You may qualify for the Achtar study if you have persistently active SLE, are 18 years of age or older, and: Have rash and/or arthritis as part of your SLE symptoms Are currently taking prednisone (or equivalent) as part of your SLE treatment. Additional requirements apply. If you qualify and agree to participate, the study treatment and study-related care will be provided to you at no cost.
This study is closed
Investigator
Anca Askanase, MD, MPH
Do You Qualify?
Are you 18 years or older? Yes No
Do you have persistently active systempic lupus erythematosus (SLE)? Yes No
Do you have a rash and/or arthritis as part of your SLE symptoms? Yes No
Are you currently taking prednisone (or equivalent) as part of your SLE treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Anca Askanase, MD
ada20@cumc.columbia.edu
212-342-6815
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE